Mersana Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Mersana Therapeutics's estimated annual revenue is currently $43k per year.
- Mersana Therapeutics received $33.0M in venture funding in June 2016.
- Mersana Therapeutics's estimated revenue per employee is $169
- Mersana Therapeutics's total funding is $480.6M.
- Mersana Therapeutics's current valuation is $451.6M. (January 2022)
Employee Data
- Mersana Therapeutics has 255 Employees.
- Mersana Therapeutics grew their employee count by 31% last year.
Mersana Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $13.8M | 73 | -39% | $107.3M | N/A |
#2 | $0.2M | 1 | 0% | N/A | N/A |
#3 | $3.1M | 26 | 63% | N/A | N/A |
#4 | $29.6M | 125 | 18% | $351M | N/A |
#5 | $15.8M | 84 | -18% | $312.8M | N/A |
#6 | $0.5M | 7 | 17% | N/A | N/A |
#7 | $235M | 269 | -43% | $340.9M | N/A |
#8 | $2.2M | 28 | 4% | N/A | N/A |
#9 | $0.6M | 10 | -9% | N/A | N/A |
#10 | $0.5M | 9 | 29% | N/A | N/A |
What Is Mersana Therapeutics?
Mersana is rewriting the rules for immunoconjugate therapies by leveraging our Fleximer platform to create precisely targeted and highly tailored drugs that radically improve patients lives. Our Fleximer platform allows us to custom design an ADC with specific properties to overcome limitations of current ADC approaches and increase the drug's chances of effectively attacking a particular cancer. We engineer immunoconjugates to deliver industry-leading payloads of an array of anti-tumor agents directly to cancerous cells, controlling when, where and how those agents are released. Because we can safely deliver higher quantities of therapeutic payloads directly to a tumor, Mersana's ADC therapies have the potential to more effectively treat broader populations of cancer patients while significantly reducing the side effects associated with many of today's cancer treatments.
keywords:N/A
$480.6M
Total Funding
255
Number of Employees
$43k
Revenue (est)
31%
Employee Growth %
$451.6M
Valuation
N/A
Accelerator
Mersana Therapeutics News
What Does The Institutional Ownership Tell Us About Mersana Therapeutics? Institutional investors commonly compare their own returns to the...
Is Mersana Therapeutics Inc (MRSN) Stock a Smart Investment Thursday? Thursday, April 21, 2022 10:41 AM | InvestorsObserver Analysts. Is Mersana...
CAMBRIDGE, Mass., April 05, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company...
CAMBRIDGE, Mass., April 07, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced th ...
Mersana Therapeutics Inc (NASDAQ:MRSN) has been given a consensus rating of “Buy” by the eight research firms that are presently covering ...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.2M | 255 | 10% | N/A |
#2 | $78.9M | 259 | -3% | $3M |
#3 | $60.1M | 261 | 31% | $81M |
#4 | $28.2M | 261 | 61% | $202.2M |
#5 | $54.4M | 262 | 21% | N/A |
Mersana Therapeutics Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2008-10-27 | $4.0M | Undisclosed | Article | |
| 2012-08-01 | $27.0M | A-1 | New Enterprise Associates | Article |
| 2013-10-15 | $5.0M | Undisclosed | Article | |
| 2014-04-10 | $14.5M | A | Article | |
| 2015-03-03 | $35.0M | B-1 | New Enterprise Associates | Article |
| 2016-06-17 | $33.0M | C | Wellington Management Company | Article |